Review
PARP inhibitors: what we know and what we have yet to know
Affiliations
- PMID: 20187323
Item in Clipboard
Review
PARP inhibitors: what we know and what we have yet to know
Oncology (Williston Park).
2010 Jan.
Free article
No abstract available
Comment on
-
Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.Oncology (Williston Park). 2010 Jan;24(1):55-62. Oncology (Williston Park). 2010. PMID: 20187322 Review.
Similar articles
-
Development of PARP inhibitors: an unfinished story.Oncology (Williston Park). 2010 Jan;24(1):66, 68. Oncology (Williston Park). 2010. PMID: 20187324 Review. No abstract available.
-
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.Future Oncol. 2010 Apr;6(4):485-6. doi: 10.2217/fon.10.27. Future Oncol. 2010. PMID: 20373860 No abstract available.
-
PARP inhibitors: targeting the right patients.J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10. J Natl Cancer Inst. 2012. PMID: 23231976 No abstract available.
-
PARP inhibitors: will the new class of drugs match the hype?J Natl Cancer Inst. 2009 Sep 16;101(18):1230-2. doi: 10.1093/jnci/djp315. Epub 2009 Sep 8. J Natl Cancer Inst. 2009. PMID: 19738163 No abstract available.
-
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22. Clin Cancer Res. 2014. PMID: 24270682 Review.
Cited by
-
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.J Hematol Oncol. 2011 Apr 20;4:16. doi: 10.1186/1756-8722-4-16. J Hematol Oncol. 2011. PMID: 21504625 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
